You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CABERGOLINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Cabergoline patents expire, and when can generic versions of Cabergoline launch?

Cabergoline is a drug marketed by Actavis Labs Fl Inc, Apotex Corp, Impax Labs Inc, Ingenus Pharms Llc, Ivax Sub Teva Pharms, Norvium Bioscience, Skg Pharma, Strides Pharma, and Welding. and is included in nine NDAs.

The generic ingredient in CABERGOLINE is cabergoline. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the cabergoline profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cabergoline

A generic version of CABERGOLINE was approved as cabergoline by STRIDES PHARMA on December 29th, 2005.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CABERGOLINE?
  • What are the global sales for CABERGOLINE?
  • What is Average Wholesale Price for CABERGOLINE?
Summary for CABERGOLINE
Drug patent expirations by year for CABERGOLINE
Drug Prices for CABERGOLINE

See drug prices for CABERGOLINE

Recent Clinical Trials for CABERGOLINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
McGill University Health Centre/Research Institute of the McGill University Health CentrePhase 4
Northwestern UniversityPhase 4
University of AarhusN/A

See all CABERGOLINE clinical trials

Pharmacology for CABERGOLINE
Drug ClassErgot Derivative

US Patents and Regulatory Information for CABERGOLINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl Inc CABERGOLINE cabergoline TABLET;ORAL 078035-001 Apr 21, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Skg Pharma CABERGOLINE cabergoline TABLET;ORAL 218618-001 Jun 26, 2024 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ingenus Pharms Llc CABERGOLINE cabergoline TABLET;ORAL 204735-001 Aug 1, 2018 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Strides Pharma CABERGOLINE cabergoline TABLET;ORAL 076310-001 Dec 29, 2005 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for CABERGOLINE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Ceva Santé Animale Velactis cabergoline EMEA/V/C/003739
For use in the herd management programme of dairy cows as an aid in the abrupt drying-off by reducing milk production to:reduce milk leakage at drying off;reduce the risk of new intramammary infections during the dry period;reduce discomfort.
Withdrawn no no no 2015-12-09
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.